4//SEC Filing
Richard King Mellon Foundation 4
Accession 0000899243-19-013252
CIK 0001563880other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 5:00 PM ET
Size
10.5 KB
Accession
0000899243-19-013252
Insider Transaction Report
Form 4
Richard King Mellon Foundation
10% Owner
Transactions
- Purchase
Common Stock
2019-05-09$10.00/sh+100,000$1,000,000→ 347,157 total - Conversion
Common Stock
2019-05-09+222,816→ 222,816 total - Other
Common Stock
2019-05-09+24,341→ 247,157 total - Conversion
Series C Preferred Stock
2019-05-09−1,908,450→ 0 total→ Common Stock (222,816 underlying)
Footnotes (2)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Consists of shares transferred to Richard King Mellon Foundation by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
IncorporatedPA
Related Parties
1- filerCIK 0001774767
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 5:00 PM ET
- Size
- 10.5 KB